Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | NAPEPLD | Q6IQ20 | 4/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | DNM1L | O00429 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2178719 | 0.99 | HSD11B1 (0.46) | HSD11B1PDE10ANAPEPLDMCHR1ALDH1A1 | |
| SCHEMBL12408685 | 0.83 | PDE10A (0.54) | HSD11B1PDE10ANAPEPLDMCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14775731 | 0.83 | PDE10A (0.53) | HSD11B1PDE10ANAPEPLDMCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2178300 | 0.68 | PDE10A (0.53) | PDE10ANAPEPLDALDH1A1NPC1RAB9A | |
| SCHEMBL30039371 | 0.66 | CD38 (0.65) | HSD11B1CYP2C19 | |
| SCHEMBL2181157 | 0.66 | PDE10A (0.47) | HSD11B1PDE10ANAPEPLDMCHR1ALDH1A1 | |
| SCHEMBL2181159 | 0.66 | PDE10A (0.47) | HSD11B1PDE10ANAPEPLDMCHR1ALDH1A1 | |
| SCHEMBL2591980 | 0.65 | HSD11B1 (1.00) | HSD11B1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28111774 | 0.64 | HSD11B1 (0.66) | HSD11B1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28836147 | 0.63 | CNR2 (0.60) | HSD11B1NPC1RAB9ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | PDE10A, PDE3A, PDE3B | HSD11B1 813/4885PDE10A 1/4885NAPEPLD 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.